NEWS 94 FEED & ADDITIVE MAGAZINE November 2024 A new study found that using whole Asparagopsis seaweed as a cattle feed additive is significantly more effective at reducing methane emissions than using bromoform, the aquatic plant's primary active compound, on its own. The study allegedly provides strong validation for the approach taken by CH4 Global, a company that aims to scale commercial production and distribution of an Asparagopsis-based feed additive as a natural solution for shrinking the climate impact of cattle farming. The peer-reviewed, in vitro study, published in Animal Feed Science and Technology, compared the methane reduction potential of whole Asparagopsis taxiformis seaweed to pure bromoform when used as feed additives for cattle. The results showed that the whole, dried seaweed reduced methane emissions by 95.6% when included at 0.5% of the diet, compared to a 59.6% reduction from an equivalent dose of bromoform. This reportedly suggests that while bromoform is the primary active compound in Asparagopsis responsible for methane reduction, other bioactive compounds in the seaweed play a significant role, accounting for approximately 40% of the total reduction effect. "Our findings demonstrate the superior efficacy of whole Asparagopsis seaweed compared to isolated bromoform in mitigating methane emissions from cattle," said Dr. Eslam K. Ahmed of Obihiro University of Agriculture and Veterinary Medicine, Japan, the study's lead researcher. "This reinforces the value of harnessing the full spectrum of bioactive compounds naturally present in the seaweed to reduce enteric methane." Read more>> Elanco Animal Health unleashed the first ever real-world data demonstrating the efficacy and impact of its Canine Parvovirus Monoclonal Antibody (CPMA), the first and only USDA Conditionally Approved targeted treatment for canine parvovirus. Annually, canine parvovirus affects more than 330,000 puppies, contributing up to a staggering 91% mortality rate without supportive care. The real-world data, collected over the first year of CPMA availability, shows improvements in survival rates for puppies battling the deadly virus as well as enhanced operational efficiency and high satisfaction within veterinary clinics – serving as a proof point that the Canine Parvovirus Monoclonal Antibody is re-writing the protocol for parvovirus treatment. "Earlier this year, Elanco launched a bold mission to save 1 million puppies from parvovirus by 2030. I'm proud that in the first year, thousands of puppies have been saved as a result of the Canine Parvovirus Monoclonal Antibody, including Cookie, Mono and Luna, to name a few," explains Bobby Modi, Executive Vice President, U.S. Pet Health at Elanco. Read more>> New study shows methane reducing effect of seaweed New data suggests Elanco's mAb treatment improves puppy survival rates
RkJQdWJsaXNoZXIy MTUxNjkxNQ==